Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: A systematic review and meta-analysis

Resource type: Publication Publication
  • Authors
    Schneidewind L.; Kiss B.; Zengerling F.; Borkowetz A.; Graf S.; Kranz J.; Drager D.L.; Graser A.; Bellut L.; Uhlig A.
  • Type
    Original research
  • Journal
    Journal of Cancer Research and Clinical Oncology
  • Publication Date
    2023
  • Abstract

    Purpose: To analyze gender-specific differences in survival parameters in advanced or metastatic urothelial cancer patients undergoing immune checkpoint inhibition.

    Method(s): The primary aim of this systematic review and meta-analysis was to evaluate gender-specific differences in disease-free (DFS), progression-free (PFS), cancer-specific survival (CSS), event-free survival (EFS), overall survival (OS) and objective response rate (ORR). The sources MEDLINE, Embase and Cochrane Library were systematically searched from January 2010 to June 2022. No restrictions were made concerning language, study region or publication type. A comparison of gender-specific differences in survival parameters was performed using a random-effects meta-analysis. A risk of bias assessment was done using the ROBINS-I tool.

Access Publication